• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Cart
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Cart
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma

byTeddy Guo
April 5, 2023
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click to read this study in The Lancet Oncology. 

RELATED REPORTS

Intraarterial dexamethasone may be effective for pain relief following uterine fibroid embolization

2 Minute Medicine Rewind August 3rd, 2026

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

Tags: blood cancercarfilzomibdexamethasonehematologic malignancyhematologylenalidomidemultiple myeloma
Previous Post

Antidepressants may improve symptoms in patients with inflammatory bowel disease

Next Post

Cardiac arrest survival during delivery lowest in those with disseminated intravascular coagulation

RelatedReports

Elagolix with add-back hormone therapy effective in reducing fibroid-associated menstrual bleeding
Chronic Disease

Intraarterial dexamethasone may be effective for pain relief following uterine fibroid embolization

August 5, 2026
Elagolix with add-back hormone therapy effective in reducing fibroid-associated menstrual bleeding
Weekly Rewinds

2 Minute Medicine Rewind August 3rd, 2026

August 3, 2026
Combined lenalidomide and rituximab dose escalation found to be safe for CLL
All Specialties

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

June 8, 2026
Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Cardiology

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

April 9, 2026
Next Post

Cardiac arrest survival during delivery lowest in those with disseminated intravascular coagulation

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail

Incongruency between patients’ values and comfort-focused care on maintenance dialysis

The American Heart Association's Life Essential 8 scores to predict cardiovascular health

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • mFlusiva becomes the first mRNA influenza vaccine approved by the FDA
  • Many patients using patient portals may not fully understand results of laboratory testing
  • Single-dose CRISPR therapy reduces hereditary angioedema attacks
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Cart
    • Sign-in
    • My account
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.